Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New DPP-IV inhibitors discovered at Syrrx

Feb. 1, 2005

New MCHR antagonists for obesity and other uses reported by Banyu

Feb. 1, 2005

Kowa scientists describe new compounds for diabetes and related complications

Feb. 1, 2005

Thiazolidinediones show promise in the treatment of diabetic vascular complications

Feb. 1, 2005

Kissei prepares and tests new agents for hyperuricemia

Jan. 31, 2005

Pfizer team describes novel series of PPARalpha activators

Jan. 31, 2005

Novartis researchers claim PPAR modulators

Jan. 31, 2005

Norditropin NordiFlex now available in U.S.

Jan. 31, 2005

Aradigm closes restructured licensing agreement with Novo Nordisk

Jan. 31, 2005

Good safety profile found for KUR-1246 in pregnant sheep

Jan. 31, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...